Filing Flows › Pharma-Bio Serv (PBSV) › Q4 FY25
Pharma-Bio Serv (PBSV) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Jan 29, 2026
Pharma-Bio Serv (PBSV) reported revenue of $2.1M for the fourth quarter fiscal 2025 (Q4 FY25), -8% from a year earlier and +10% from the quarter before. Operating margin was -6.2%, net loss $102 (0.0% of revenue).
Pharma-Bio Serv, Q4 FY25: revenue $2.1M (-8% year over year), operating margin -6.2%, net loss $102, operating cash flow $280K. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.1M | +10% | -8% |
| Operating profit | −$133K | — | — |
| Net earnings | −$102 | — | -101% |
| Operating cash flow | $280K | +18% | +257% |
| Free cash flow | $279K | +19% | — |
What changed
Revenue was $2.1M in Q4 FY25, down 8% year over year and up 10% from the previous quarter.
Gross margin was 34.8%, up 3.7 points from Q4 FY24. Operating costs exceeded revenue by $133K, an operating margin of -6.2%. Operating expenses grew 0% against a revenue fall of 8%. The quarter ended with a net loss of $0K, narrower than the previous quarter's $204K loss. Non-operating items added $138K, 3233% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $280K (up 257% year over year). Non-cash charges added back $16K of depreciation and amortization and $4K of share-based compensation. Working capital and other items added $260K. Capital expenditures of $0K left free cash flow of $279K.
Questions
What was Pharma-Bio Serv's revenue in the fourth quarter fiscal 2025?
Pharma-Bio Serv (PBSV) reported revenue of $2.1M for the fourth quarter fiscal 2025 (Q4 FY25), -8% from a year earlier and +10% from the quarter before.
Was Pharma-Bio Serv profitable in the fourth quarter fiscal 2025?
Operating loss was $133K (-6.2% of revenue) and net loss $102.
Source: Pharma-Bio Serv 10-K on SEC EDGAR.